This webinar provides a detailed look at Japan's 2nd largest research based pharmaceutical company. Our guest speaker from Astellas explains their strategy for product development and examples of partnership opportunities your company could engage with.
Astellas Pharma Inc has the vision to become a “Global Category Leader (GCL)” by strengthening their competitiveness by providing high value added products on a global basis in specialised areas where a greater degree of unmet medical needs exist. The company has already established their strong presence in the areas of Urology and Immunology (including Transplantation) and Infectious diseases, and has the aim to strengthen oncology as one of the company’s core pillars for business. Astellas Phama Inc also have a focus on Neuroscience and DM Complications and Kidney diseases.
Astellas formed a number of business partnership agreements in the recent years, including Cubist Pharmaceutical Inc in March 2013 and Cytokinetics Inc in June 2013. They have also formed a strategic alliance with Amgen and created Amgen Astellas BioPharma KK to co-develop and co-commercialise Amgen’s pipeline products in the Japanese market.
Astellas Pharma Inc's core therapeutic areas include:
2. Inflammatory and Immunology
3. Infectious diseases (virus)
4. CNS and Pain
They are also engaged in vaccine development.
Mr Chihiro Yokota, Corporate Executive, Global Head of Business Development and Licensing & Alliances
Mr Yokota has more than 30 years of pharmaceutical industry experience with Fujisawa Pharmaceutical Co., Ltd. and Astellas Pharma Inc. He currently leads Astellas’ Global Business Development / Licensing & Alliances activities, including deals such as the acquisition of OSI Pharmaceuticals, and alliances with Medivation, Vical, UCB, Amgen, Merck, Cytokinetics, Mitokyne and others.
Prior to his current position, he served as Global Head of Project Management at Astellas Pharma Global Development. He also previously held the position of Vice President of Clinical Research at Fujisawa Research Institute of America, Inc. based in the US.
During the webinar, Mr. Yokota explains Astellas’ business and partnering strategies and areas of potential collaboration opportunities for UK companies with Astellas Pharma Inc.
This webinar was recorded live at the British Embassy Tokyo on 3rd April 2014 and is available to members of the Export to Japan website.